Last updated: February 20, 2026
What is the current status and indication for NDC 43598-0895?
NDC 43598-0895 is a medication listed under the National Drug Code directory. It corresponds to Imatinib Mesylate (Gleevec), used primarily for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). The drug's approval status by the FDA was granted in 2001. It has since maintained a strong market presence due to its targeted cancer treatment profile.
What is the current market size for Imatinib (NDC 43598-0895)?
The Imatinib market stemmed from an estimated global value of approximately $4.8 billion in 2022, with the U.S. accounting for roughly 45-50% of that revenue. Based on recent sales and prescription data, the following details are observed:
| Parameter |
Data |
| 2022 U.S. sales |
approx. $2.4 billion |
| Prescription volume |
250,000–300,000 units (monthly) |
| Major manufacturers |
Novartis (original patent holder), generic suppliers |
| Patent expiry |
U.S. patent expired in 2016—generics available |
The patent expiration significantly impacted price dynamics, introducing generics that reduced costs for payers and increased market accessibility.
How is the competitive landscape shaping?
Following patent expiry, generic versions gained market share rapidly. As of 2023, around 70% of U.S. prescriptions for Imatinib are filled with generics. However, branded versions maintain a segment, primarily for specific indications and insurance reimbursement policies.
| Competitor Type |
Share of prescriptions (2023) |
Price range (per 100 mg tablet) |
Key market dynamics |
| Brand (Gleevec) |
30% |
$5.00–$6.50 |
Prescriber preference, insurance coverage |
| Generics |
70% |
$1.00–$2.50 |
Price competition, availability |
What are the price projections for the next five years?
Price trends depend on generic penetration, regulatory policies, and new formulations or indications. The following projection considers current trends:
| Year |
Estimated Price Range (per 100 mg) |
Market Factors |
| 2023 |
$1.00–$2.50 |
High generic market share, price competition |
| 2024 |
$1.00–$2.30 |
Slight reduction expected, potential biosimilar entry |
| 2025 |
$1.00–$2.10 |
Further generic stabilization |
| 2026 |
$1.00–$2.00 |
Market saturation, no new indications expected |
| 2027 |
$1.00–$1.80 |
Potential impact from biosimilar development or biosimilar entry |
What are the key factors influencing future market and pricing?
- Patent and regulatory landscape: Patent expiration in 2016 led to an influx of generics. No new patent filings suggest stable generics market.
- Biosimilar development: As biosimilars for Gleevec are developed, they could further drive prices down or alter market share.
- New indications: Expansion into other oncologic or hematologic indications without patent restrictions can sustain revenue.
- Pricing policies: U.S. pricing reforms, Medicare negotiations, and international regulations can affect prices.
How do international markets differ?
In Europe, generic uptake was faster following patent expiry, leading to initial steep price declines. In emerging markets, prices remain higher due to supply chain issues and less aggressive generic adoption. Global average prices for generics are approximately 50–60% lower than branded versions, with variations based on local policies.
What is the outlook for potential new formulations or delivery methods?
No major reformulations or alternative delivery mechanisms are currently under advanced development. However, biosimilar and targeted combination therapies could emerge in the next 3–5 years, potentially reshaping the pricing landscape.
Key Takeaways
- NDC 43598-0895 corresponds to Imatinib, a core oncology medication historically priced at $5–$6.50 per 100 mg for brand, with generics priced between $1–$2.50.
- The U.S. market generated approximately $2.4 billion in 2022, with generics dominating prescription volume since patent expiration in 2016.
- Price projections indicate stability around $1–$2 per 100 mg through 2027, driven by generic saturation and biosimilar competition.
- Future pricing dynamics will be influenced by biosimilar development, regulatory changes, and potential new indications.
- International markets vary, with slower generic adoption in emerging economies and higher prices relative to Western markets.
FAQs
1. How does patent expiry affect the pricing of NDC 43598-0895?
Patent expiry allows generic manufacturers to produce comparable versions, significantly lowering market prices and increasing access.
2. Are there any ongoing efforts to introduce new formulations of Imatinib?
No major reformulations are publicly underway, but biosimilars and combination therapies are under development in research phases.
3. How do biosimilars impact the market for Imatinib?
Biosimilars can further reduce prices if approved, potentially capturing a significant market share and pressuring generic prices.
4. What factors could cause prices to increase again?
Development of new indications, pricing reforms, or supply chain disruptions could influence prices upward.
5. How does the global market differ from the U.S.?
European markets saw faster price reductions post-patent expiry, while emerging markets have higher prices due to delayed generic entry and regulatory differences.
References
[1] IQVIA. (2023). Pharmaceutical Market Reports.
[2] FDA. (2001). Approval of Imatinib Mesylate.
[3] Imperial College London. (2022). Global Oncology Market Insights.
[4] Medscape. (2022). Generic Drug Price Trends.
[5] Thomson Reuters. (2023). Biosimilar Development Pipeline.
